<DOC>
	<DOCNO>NCT02220725</DOCNO>
	<brief_summary>The purpose study evaluate ability Andexanet Alfa reverse anticoagulation effect Rivaroxaban .</brief_summary>
	<brief_title>A Study Older Subject Evaluate Safety Ability Andexanet Alfa Reverse Anticoagulation Effect Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Reasonably healthy men woman age 50 75 History abnormal bleeding , active bleeding risk factor bleed History thrombosis risk factor thrombosis History adult asthma use inhale medication</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Andexanet alpha</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Antidote</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Anti-fXa inhibitor</keyword>
	<keyword>PRT4445</keyword>
	<keyword>Xarelto</keyword>
	<keyword>Reversal agent</keyword>
</DOC>